Comparative Pharmacology
Head-to-head clinical analysis: LENALIDOMIDE versus POMBILITI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LENALIDOMIDE versus POMBILITI.
LENALIDOMIDE vs POMBILITI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunomodulatory agent with anti-angiogenic and anti-proliferative properties; alters cytokine production, enhances T-cell and NK-cell activity, inhibits tumor angiogenesis, and directly induces apoptosis in tumor cells.
POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.
10 mg orally once daily on days 1-21 of 28-day cycle for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes; 25 mg orally once daily on days 1-21 of 28-day cycle for relapsed/refractory multiple myeloma.
500 mg orally twice daily
None Documented
None Documented
Clinical Note
moderateLenalidomide + Digitoxin
"Lenalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLenalidomide + Deslanoside
"Lenalidomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLenalidomide + Acetyldigitoxin
"Lenalidomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateLenalidomide + Ouabain
"Lenalidomide may decrease the cardiotoxic activities of Ouabain."
Terminal half-life ~3 hours (range 2-5 h) in multiple myeloma patients; prolongation in renal impairment requires dose adjustment.
Terminal elimination half-life is approximately 11 hours (range 6.5–19 h). Clinical context: supports twice-daily dosing with moderate accumulation; half-life prolonged in hepatic impairment.
Renal: ~82% unchanged; fecal <5%; biliary negligible.
Primarily biliary-fecal (77% of absorbed dose) and renal (23% unchanged) with enterohepatic recirculation.
Category C
Category C
Immunomodulatory Agent
Immunomodulatory Agent